Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Taranabant study shows weight loss, metabolic benefits after one year

April 2, 2008

Vivus and FDA agree on safety study and SPA for phase III trials of Luramist for HSDD

April 2, 2008

Recent patents describe new treatment options for endocrine disorders

April 2, 2008

Merck & Co. places on hold further patient enrollment in ACHIEVE study of Cordaptive

April 2, 2008

IMPACT1 study demonstrates efficacy of Berinert P in hereditary angioedema

April 1, 2008

New therapeutic agents for diabetic nephropathy described in recent Kowa patent

April 1, 2008

Encouraging results reported in first clinical trial of efficacy for GFT-505

April 1, 2008

AnGes receives approval to manufacture and market Naglazyme for MPS VI

March 31, 2008

KY-201 shows better safety profile than rosiglitazone in preclinical studies

March 31, 2008

Karo Bio initiates second phase IIb clinical study of eprotirome in dyslipidemia

March 31, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...